Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 1922

BillFederalHouseIn Committee
Ensuring Access to Essential Drugs Act
About This Bill
Committee
Latest Action · March 6, 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress
119th (2025–2027)
Introduced
March 6, 2025
Cosponsors (2)
1D 1R
View PDF ↗

Summary

Highlight any text to annotate
Ensuring Access to Essential Drugs Act This bill exempts certain brand-name drugs from the Medicare Part D Manufacturer Discount Program. Under the program, drug manufacturers provide discounts to beneficiaries who have incurred costs above the annual deductible under the Medicare prescription drug benefit. Specifically, the bill exempts from the program orally administered, brand-name drugs that are considered generics for purposes of the Medicaid Drug Rebate Program (per an exception granted by the Centers for Medicare & Medicaid Services).

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.